UPDATE: BofA Securities Reinstates GoodRx Holdings Inc. (GDRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Bragar Eagel & Squire, P.C. Is Investigating TG Therapeutics, GoodRx, Agrify, and Pegasystems and Encourages Investors to Contact the Firm
June 3, 2022 9:00 PM EDTNEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TG Therapeutics, Inc. (NASDAQ: TGTX), GoodRx Holdings, Inc. (NASDAQ: GDRX), Agrify Corporation (NASDAQ: AGFY), and Pegasystems, Inc. (NASDAQ: PEGA). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
